Old Borders and New Horizons in Multimodality Imaging of Malignant Pleural Mesothelioma

Martini, Katharina; Frauenfelder, Thomas

doi:10.1055/s-0041-1728714

Cited by 3 publications

(2 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…27 Recently, there has been interest in the use of diffusion-weighted MRI to further classify benign from malignant pleural diseases as well as histology of mesothelioma 28,29 ; however, further studies have not validated MRI histologic differentiation of mesothelioma. A variety of novel radiomic algorithms for further image classification of pleural mesothelioma are under investigation, [30][31][32] with the goal of defining growth of the disease, but these studies are not currently mature.…”

Section: Radiology Technologymentioning

confidence: 99%

New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options

Tsao

Pass

Rimner

et al. 2022

JCO

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is a rare malignancy with few treatment options. Recent advances have led to US Food and Drug Administration approvals and changes in the standard of care with a novel biomedical device approved for use with platinum-pemetrexed, and also for immunotherapy agents to be included as a frontline treatment option in unresectable disease. Although predictive biomarkers for systemic therapy are not currently in use in clinical practice, it is essential to correctly identify the MPM histology to determine an optimal treatment plan. Patients with nonepithelioid MPM may have a greater magnitude of benefit to dual immunotherapy checkpoint inhibitors and this regimen should be preferred in the frontline setting for these patients. However, all patients with MPM can derive benefit from immunotherapy treatments, and these agents should ultimately be used at some point during their treatment journey. There are ongoing studies in the frontline unresectable setting that may further define the frontline therapy space, but a critical area of research will need to focus on the immunotherapy refractory population. This review article will describe the new developments in the areas of biology with genomics and chromothripsis, and also focus on updates in treatment strategies in radiology, surgery, radiation, and medical oncology with cellular therapies. These recent innovations are generating momentum to find better therapies for this disease.

show abstract

Section: Radiology Technologymentioning

confidence: 99%

New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options

Tsao

Pass

Rimner

et al. 2022

JCO

View full text Add to dashboard Cite

show abstract

“…Diffusion-weighted imaging (DWI) allows patient-tailored care in MPM: it has already been used to discriminate between long-and short-term overall survivors [50]. Several new tools have been developed in the last year for a multi-parametric evaluation of tumor lesions (e.g., Dynamic Contrast-Enhanced MR Imaging, Chemical Exchange Saturation Transfer Imaging) [51]. IVIM-based perfusion MRI, which does not require contrast agents, is gaining momentum, especially for oncologic applications [52,53].…”

Section: Imaging As a Tool To Assess Tumor Micro-environmentmentioning

confidence: 99%

Local Therapies and Modulation of Tumor Surrounding Stroma in Malignant Pleural Mesothelioma: A Translational Approach

Lisini

Lettieri

Nava

et al. 2021

IJMS

View full text Add to dashboard Cite

Malignant Pleural Mesothelioma (MPM) is a rare and aggressive neoplasm of the pleural mesothelium, mainly associated with asbestos exposure and still lacking effective therapies. Modern targeted biological strategies that have revolutionized the therapy of other solid tumors have not had success so far in the MPM. Combination immunotherapy might achieve better results over chemotherapy alone, but there is still a need for more effective therapeutic approaches. Based on the peculiar disease features of MPM, several strategies for local therapeutic delivery have been developed over the past years. The common rationale of these approaches is: (i) to reduce the risk of drug inactivation before reaching the target tumor cells; (ii) to increase the concentration of active drugs in the tumor micro-environment and their bioavailability; (iii) to reduce toxic effects on normal, non-transformed cells, because of much lower drug doses than those used for systemic chemotherapy. The complex interactions between drugs and the local immune-inflammatory micro-environment modulate the subsequent clinical response. In this perspective, the main interest is currently addressed to the development of local drug delivery platforms, both cell therapy and engineered nanotools. We here propose a review aimed at deep investigation of the biologic effects of the current local therapies for MPM, including cell therapies, and the mechanisms of interaction with the tumor micro-environment.

show abstract

Transfer learning approach in pre-treatment CT images to predict therapeutic response in advanced malignant pleural mesothelioma

Fanizzi,

Catino,

Bove

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

IntroductionMalignant pleural mesothelioma (MPM) is a poor-prognosis disease. Owing to the recent availability of new therapeutic options, there is a need to better assess prognosis. The initial clinical response could represent a useful parameter.MethodsWe proposed a transfer learning approach to predict an initial treatment response starting from baseline CT scans of patients with advanced/unresectable MPM undergoing first-line systemic therapy. The therapeutic response has been assessed according to the mRECIST criteria by CT scan at baseline and after two to three treatment cycles. We used three slices of baseline CT scan as input to the pre-trained convolutional neural network as a radiomic feature extractor. We identified a feature subset through a double feature selection procedure to train a binary SVM classifier to discriminate responders (partial response) from non-responders (stable or disease progression).ResultsThe performance of the prediction classifiers was evaluated with an 80:20 hold-out validation scheme. We have evaluated how the developed model was robust to variations in the slices selected by the radiologist. In our dataset, 25 patients showed an initial partial response, whereas 13 patients showed progressive or stable disease. On the independent test, the proposed model achieved a median AUC and accuracy of 86.67% and 87.50%, respectively.ConclusionsThe proposed model has shown high performance even by varying the reference slices. Novel tools could help to improve the prognostic assessment of patients with MPM and to better identify subgroups of patients with different therapeutic responsiveness.

show abstract

Old Borders and New Horizons in Multimodality Imaging of Malignant Pleural Mesothelioma

Cited by 3 publications

References 52 publications

New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options

New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options

Local Therapies and Modulation of Tumor Surrounding Stroma in Malignant Pleural Mesothelioma: A Translational Approach

Transfer learning approach in pre-treatment CT images to predict therapeutic response in advanced malignant pleural mesothelioma

Contact Info

Product

Resources

About